CIK 0001231457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
GENELUX Corp
Sign in to watch- Ticker
- GNLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 805-267-9889
- Business address
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $155,693
- in 6 filings
Net −$155,693. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 71 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-27 | Cappello Joseph Chief Technical Officer | Grant or award | +107,500 | 159,766 | ||
| 2025-08-27 | Cappello Joseph Chief Technical Officer | Grant or award · Stock Option (Right to Buy) | +142,500 | 142,500 | ||
| 2025-08-21 | Zindrick Thomas President and CEO | Sale | −12,673 | $3.33 | $42K | 542,940 |
| 2025-08-21 | Yu Yong SVP, Clinical Development | Sale | −3,219 | $3.36 | $11K | 146,817 |
| 2025-08-21 | Cappello Joseph Chief Technical Officer | Sale | −1,270 | $3.33 | $4K | 158,496 |
| 2025-08-21 | Cappello Joseph Chief Technical Officer | Sale | −1,463 | $3.36 | $5K | 157,033 |
| 2025-08-21 | Smalling Ralph Head of Regulatory | Sale | −1,244 | $3.36 | $4K | 69,746 |
| 2025-07-01 | Groen Eric General Counsel & Secretary | Grant or award · Stock Option (Right to Buy) | +270,000 | 270,000 | ||
| 2025-06-06 | Thomas John Director | Gift | −25,000 | 480,501 | ||
| 2025-05-12 | Ryder Sean General Counsel | Sale | −4,475 | $2.92 | $13K | 47,621 |
| 2025-05-12 | Zindrick Thomas President and CEO | Sale | −10,764 | $2.92 | $31K | 191,447 |
| 2025-05-12 | Yu Yong VP, Clinical Trial Operations | Sale | −5,579 | $2.92 | $16K | 47,640 |
| 2025-05-12 | Cappello Joseph VP, Pharmaceutical Development | Sale | −4,737 | $2.92 | $14K | 52,266 |
| 2025-05-12 | Smalling Ralph Head of Regulatory | Sale | −1,259 | $2.92 | $4K | 34,760 |
| 2025-03-14 | Smalling Ralph Head of Regulatory | Grant or award | +4,172 | 36,019 | ||
| 2025-03-14 | Cappello Joseph VP, Pharmaceutical Development | Grant or award | +13,350 | 57,003 | ||
| 2025-03-14 | Yu Yong VP, Clinical Trial Operations | Grant or award | +13,350 | 53,219 | ||
| 2025-03-14 | Ryder Sean General Counsel | Grant or award | +10,708 | 52,096 | ||
| 2025-03-14 | Zindrick Thomas President and CEO | Grant or award | +30,339 | 202,211 | ||
| 2025-01-31 | Pulisic Matthew Chief Financial Officer | Grant or award · Stock Option (right to buy) | +275,000 | 275,000 |
Page 5 of 9 · 170 trades